CFDB - Cystic Fibrosis DataBase

primary studies published RCT

Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?.

Study design (if review, criteria of inclusion for studies)

controlled study


22 children with severe CF hospitalized with respiratory exacerbations


cloxacillin or carbenicillin plus gentamicin administered intravenously for ten days

Outcome measures

sputum coulture, clinical outcome, chest scores

Main results

Other aspects of therapy were constant. The groups were comparable in all respects and Pseudomonas aeruginosa was the predominant sputum pathogen in most patients. Clinical improvement, chest radiograph changes, evidence of airway obstruction, and bacteriologic flora of sputum were no different regardless of the regimen used.

Authors' conclusions

These results suggest that the use of anti-Pseudomonas medication in these children may not always be necessary. These observations need to be confirmed by blind-controlled studies in larger numbers of patients with mild as well as severe respiratory involvement.

Keywords: Anti-Bacterial Agents; Bacterial Infections; carbenicillin; Child; Cloxacillin; Combined Modality Therapy; Gentamicin; Infection; pharmacological_intervention; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections; Exacerbation; Intravenous; Penicillins; Aminoglycosides;